Pete Buzy

Pete Buzy joined Paragon Bioservices in 2014 as the Chief Operating Officer, later moving into the role of President & Chief Executive Officer. Bringing with him more than 25 years of successful executive management experience, Pete grew the company into a premier CDMO with a leading position in gene therapy and next-generation vaccines. His expertise in growing companies was instrumental in leading the company to be acquired by Catalent (NYSE: CTLT) in 2019. Catalent is the leading global provider of advanced delivery technologies, development and manufacturing solutions for drugs, biologics, gene therapies, and consumer health products.

Prior to Paragon, Pete spent more than 13 years as a senior executive at Martek Biosciences Corporation (NASDAQ: MATK), a leader in the innovation, development, production, and sale of high-value products from microbial sources. He played a key role in transforming Martek’s business from an R&D company to a fully integrated and profitable commercial organization with more than $470M in annual sales.